<?xml version="1.0" encoding="UTF-8"?>
<ref id="B53">
 <label>53.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Lambert</surname>
    <given-names>PH</given-names>
   </name>
   <name>
    <surname>Ambrosino</surname>
    <given-names>DM</given-names>
   </name>
   <name>
    <surname>Andersen</surname>
    <given-names>SR</given-names>
   </name>
   <name>
    <surname>Baric</surname>
    <given-names>RS</given-names>
   </name>
   <name>
    <surname>Black</surname>
    <given-names>SB</given-names>
   </name>
   <name>
    <surname>Chen</surname>
    <given-names>RT</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>Consensus summary report for CEPI/BC March 12-13, 2020 meeting: assessment of risk of disease enhancement with COVID-19 vaccines</article-title>. 
  <source>Vaccine.</source> (
  <year>2020</year>) 
  <volume>38</volume>:
  <fpage>4783</fpage>â€“
  <lpage>91</lpage>. 
  <pub-id pub-id-type="doi">10.1016/j.vaccine.2020.05.064</pub-id>
  <?supplied-pmid 32507409?>
  <pub-id pub-id-type="pmid">32507409</pub-id>
 </mixed-citation>
</ref>
